AMP-activated protein kinase: role in metabolism and therapeutic implications

被引:114
作者
Schimmack, Greg [1 ]
DeFronzo, Ralph A. [1 ]
Musi, Nicolas [1 ]
机构
[1] Univ Texas, Hlth Sci Ctr San Antonio, Texas Diabet Inst, San Antonio, TX 78207 USA
关键词
ACC; AMPK; exercise; glucose transport; type 2 diabetes mellitus;
D O I
10.1111/j.1463-1326.2005.00561.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
AMP-activated protein kinase (AMPK) is an enzyme that works as a fuel gauge which becomes activated in situations of energy consumption. AMPK functions to restore cellular ATP levels by modifying diverse metabolic and cellular pathways. In the skeletal muscle, AMPK is activated during exercise and is involved in contraction-stimulated glucose transport and fatty acid oxidation. In the heart, AMPK activity increases during ischaemia and functions to sustain ATP, cardiac function and myocardial viability. In the liver, AMPK inhibits the production of glucose, cholesterol and triglycerides and stimulates fatty acid oxidation. Recent studies have shown that AMPK is involved in the mechanism of action of metformin and thiazolidinediones, and the adipocytokines leptin and adiponectin. These data, along with evidence that pharmacological activation of AMPK in vivo improves blood glucose homeostasis, cholesterol concentrations and blood pressure in insulin-resistant rodents, make this enzyme an attractive pharmacological target for the treatment of type 2 diabetes, ischaemic heart disease and other metabolic diseases.
引用
收藏
页码:591 / 602
页数:12
相关论文
共 117 条
[1]   AMP-activated protein kinase plays a role in the control of food intake [J].
Andersson, U ;
Filipsson, K ;
Abbott, CR ;
Woods, A ;
Smith, K ;
Bloom, SR ;
Carling, D ;
Small, CJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (13) :12005-12008
[2]  
Astrup A, 2000, Obes Rev, V1, P57, DOI 10.1046/j.1467-789x.2000.00013.x
[3]   Weight loss in obese diabetic and non-diabetic individuals and long-term diabetes outcomes - a systematic review [J].
Aucott, L ;
Poobalan, A ;
Smith, WCS ;
Avenell, A ;
Jung, R ;
Broom, J ;
Grant, AM .
DIABETES OBESITY & METABOLISM, 2004, 6 (02) :85-94
[4]   Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: Peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach [J].
Bays, H ;
Mandarino, L ;
DeFronzo, RA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (02) :463-478
[5]   MODULATION OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE-ACTIVITY WITH CAMP AND WITH PROTEIN FRACTIONS OF RAT-LIVER CYTOSOL [J].
BEG, ZH ;
ALLMANN, DW ;
GIBSON, DM .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1973, 54 (04) :1362-1369
[6]   Effect of 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats [J].
Bergeron, R ;
Previs, SF ;
Cline, GW ;
Perret, P ;
Russell, RR ;
Young, LH ;
Shulman, GI .
DIABETES, 2001, 50 (05) :1076-1082
[7]   Effect of AMPK activation on muscle glucose metabolism in conscious rats [J].
Bergeron, R ;
Russell, RR ;
Young, LH ;
Ren, JM ;
Marcucci, M ;
Lee, A ;
Shulman, GI .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1999, 276 (05) :E938-E944
[8]   The evolution of β-cell dysfunction and insulin resistance in type 2 diabetes [J].
Bergman, RN ;
Finegood, DT ;
Kahn, SE .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2002, 32 :35-45
[9]   Insulin receptor substrate-1 phosphorylation and phosphatidylinositol 3-kinase activity in skeletal muscle from NIDDM subjects after in vivo insulin stimulation [J].
Bjornholm, M ;
Kawano, Y ;
Lehtihet, M ;
Zierath, JR .
DIABETES, 1997, 46 (03) :524-527
[10]   Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects [J].
Boden, G ;
Lebed, B ;
Schatz, M ;
Homko, C ;
Lemieux, S .
DIABETES, 2001, 50 (07) :1612-1617